Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma

Nuclear Medicine and Biology

Volumn 39, Issue 8, 2012, Pages 1167-1172

  Park, Seok Gun ^a   Lee, Jai Hyuen ^a   Lee, Won Ae ^a   Han, Kang Min ^a  

^a Dankook University College of Medicine   (South Korea)

Author keywords

FDG PET; Glucose transporter; Hexokinase; Ki 67 and Melanoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HEXOKINASE; HEXOKINASE 2; KI 67 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; HEXOKINASE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MELANOMA; MIDDLE AGED;

EID: 84867868865     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.07.003     Document Type: Article

References (37)

1. Chi Z., Li S., Sheng X., Si L., Cui C., Han M., et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 2011, 11:85.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
3. Roh M.R., Kim J., Chung K.Y. Treatment and outcomes of melanoma in acral location in Korean patients. Yonsei Med J 2010, 51(4):562-568.
4. Bastiaannet E., Uyl-de Groot C.A., Brouwers A.H., van der Jagt E.J., Hoekstra O.S., Oyen W., et al. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma. Ann Surg 2012, 255(4):771-776.
5. Kang S., Ahn B.C., Hong C.M., Song B.I., Lee H.J., Jeong S.Y., et al. Can (18)F-FDG PET/CT predict recurrence in patients with cutaneous malignant melanoma?. Nuklearmedizin 2011, 50(3):116-121.
6. Bastiaannet E., Wobbes T., Hoekstra O.S., van der Jagt E.J., Brouwers A.H., Koelemij R., et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 2009, 27(28):4774-4780.
7. Strobel K., Skalsky J., Kalff V., Baumann K., Seifert B., Joller-Jemelka H., et al. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. Eur J Nucl Med Mol Imaging 2007, 34(9):1366-1375.
8. Fuster D., Chiang S., Johnson G., Schuchter L.M., Zhuang H., Alavi A. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?. J Nucl Med 2004, 45:1323-1327.
9. Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 1999, 40(4):591-603.
10. Yamada K., Brink I., Bisse E., Epting T., Engelhardt R. Factors influencing [F-18] 2-fluoro-2-deoxy-D-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity. J Dermatol 2005, 32:316-334.
11. Baer S.C., Casaubon L., Younes M. Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia. J Am Acad Dermatol 1997, 37(4):575-577.
12. Kim B.H., Kim I.J., Kim S.S., Kim S.J., Lee C.H., Kim Y.K. Relationship between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in incidentally detected thyroid cancer. Cancer Biother Radiopharm 2010, 25(3):309-315.
13. Paudyal B., Oriuchi N., Paudyal P., Higuchi T., Nakajima T., Endo K. Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography. Cancer Sci 2008, 99(2):260-266.
14. Ong L.C., Jin Y., Song I.C., Yu S., Zhang K., Chow P.K. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II. Acta Radiol 2008, 49(10):1145-1153.
15. Aloj L., Caraco C., Jagoda E., Eckelman W.C., Neumann R.D. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 1999, 59(18):4709-4714.
16. Kaira K., Endo M., Abe M., Nakagawa K., Ohde Y., Okumura T., et al. Biologic correlates of (1)F-FDG uptake on PET in pulmonary pleomorphic carcinoma. Lung Cancer 2011, 71(2):144-150.
17. Kaira K., Endo M., Abe M., Nakagawa K., Ohde Y., Okumura T., et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 2010, 28(23):3746-3753.
18. Higashi K., Ueda Y., Sakurai A., Wang X.M., Xu L., Murakami M., et al. Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med Mol Imaging 2000, 27(12):1778-1785.
19. Suzawa N., Ito M., Qiao S., Uchida K., Takao M., Yamada T., et al. Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size. Lung Cancer 2011, 72(2):191-198.
20. Shim H.K., Lee W.W., Park S.Y., Kim H., Kim S.E. Relationship between FDG uptake and expressions of glucose transporter type 1, type 3, and hexokinase-II in Reed-Sternberg cells of Hodgkin lymphoma. Oncol Res 2009, 17(7):331-337.
21. Parente P., Coli A., Massi G., Mangoni A., Fabrizi M.M., Bigotti G. Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions. J Exp Clin Cancer Res 2008, 27:34.
22. Qiu M.Z., Han B., Luo H.Y., Zhou Z.W., Wang Z.Q., Wang F.H., et al. Expressions of hypoxia-inducible factor-1alpha and hexokinase-II in gastric adenocarcinoma: the impact on prognosis and correlation to clinicopathologic features. Tumour Biol 2011, 32(1):159-166.
23. Gong L., Cui Z., Chen P., Han H., Peng J., Leng X. Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II. Medical Oncol 2011, 28.
24. Palmieri D., Fitzgerald D., Shreeve S.M., Hua E., Bronder J.L., Weil R.J., et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res 2009, 7(9):1438-1445.
25. Gil-Rendo A., Martinez-Regueira F., Zornoza G., Garcia-Velloso M.J., Beorlegui C., Rodriguez-Spiteri N. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 2009, 96(2):166-170.
26. Nguyen X.C., Lee W.W., Chung J.H., Park S.Y., Sung S.W., Kim Y.K., et al. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 2007, 62(2):214-219.
27. Lee J.H., Park S.G., Lee W.A., Park D.G., Namgung H. Relationship between dual-time point FDG PET and immunohistochemical parameters in preoperative colorectal cancer: preliminary study. Nucl Med Mol Imaging 2012, 46(1):48-56.
28. Aoki D., Kawakami H., Nozawa S., Udagawa Y., Iizuka R., Hirano H. Differences in lectin binding patterns of normal human endometrium between proliferative and secretory phases. Histochemistry 1989, 92(3):177-184.
29. Wachsberger P.R., Gressen E.L., Bhala A., Bobyock S.B., Storck C., Coss R.A., et al. Variability in glucose transporter-1 levels and hexokinase activity in human melanoma. Melanoma Res 2002, 12(1):35-43.
30. Younes M., Lechago L.V., Somoano J.R., Mosharaf M., Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996, 56(5):1164-1167.
31. Mathupala S.P., Rempel A., Pedersen P.L. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 1997, 29(4):339-343.
32. Mamede M., Higashi T., Kitaichi M., Ishizu K., Ishimori T., Nakamoto Y., et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005, 7(4):369-379.
33. Tian M., Zhang H., Nakasone Y., Mogi K., Endo K. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging 2004, 31(1):5-12.
34. Kaida H., Hiromatsu Y., Kurata S., Kawahara A., Hattori S., Taira T., et al. Relationship between clinicopathological factors and fluorine-18-fluorodeoxyglucose uptake in patients with papillary thyroid cancer. Nucl Med Commun 2011, 32(8):690-698.
35. Higashi T., Tamaki N., Torizuka T., Nakamoto Y., Sakahara H., Kimura T., et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998, 39(10):1727-1735.
36. Nasr M.R., El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 2008, 30(2):117-122.
37. Tran T.A., Ross J.S., Carlson J.A., Mihm M.C. Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions. Hum Pathol 1998, 29(10):1085-1090.